Therefore, premature discontinuation of oral semaglutide may be due to the fact that elderly patients may be weaker, prefer treatment once a week, and are more susceptible to gastrointestinal intolerance (Newton, 2005) combined with baseline comorbidities that complicate continuation of treatment
As evidence on the topic is accumulating rapidly, there is a need for continuous evaluation and monitoring of the benefit-harm balance to guide up-to-date decisions, they wrote
SURMOUNT-1 results (72 weeks, adults with obesity): 5 mg dose: approximately 15% body weight loss 10 mg dose: 19.5% body weight loss 15 mg dose: 22.5% body weight loss Placebo: 3.1% body weight loss At the 15 mg maximum dose, the average participant lost about 52 pounds over 72 weeks
On the other hand, having a steady supply of glutathione can help increase your bodys antioxidant activity and its ability to resist oxidative stress that can otherwise become harmful
AMMPS DA20191907626DMP/20UCA/v1 ( BiotechUSA ).
Carcinogenesis 26(7): 1256-1262
